Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. - Test2 - elhamkhani - TriplyDB

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.

http://www.wikidata.org/entity/Q37480302

about

Granzyme B cleavage of autoantigens in autoimmunity Idiopathic Inflammatory Myopathies: Clinical Approach and Management MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel.Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.MicroRNAs as biomarkers in rheumatic diseases.Clinical presentation and evaluation of dermatomyositis.Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum".Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.An overview of polymyositis and dermatomyositis.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Novel autoantibodies and clinical phenotypes in adult and juvenile myositis.Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study Myositis-specific autoantibodies: detection and clinical associations.Significance of myositis autoantibody in patients with idiopathic interstitial lung disease Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.Brief report: antisynthetase syndrome-associated myocarditis Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology Type I interferon pathway in adult and juvenile dermatomyositis.The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.Dermatomyositis in a Patient with Cholangiocarcinoma Detected by an [(18)F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan.Polymyositis and dermatomyositis as a risk of developing cancer.Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature.Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis.Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Clinical heterogeneity and outcomes of antisynthetase syndrome.

P2860

Q24633095-9216A1D7-D6EA-4EB8-BC7A-E09DFC34B3D9 Q26744705-ADACB998-1B62-4F62-A6BE-4637B12CC3CC Q26777975-5215533A-5CF9-4B27-8546-44F36C2C2EA4 Q30252086-F71662D7-C1F3-4BA2-B2C3-9A9EE3684053 Q33691192-EF3CF764-6152-4ADC-A44B-9103145E6457 Q33717793-379E57FF-16A3-4745-A01C-F1AFC97967DB Q34486301-C83B229E-22C4-4EF1-9E46-E7290264A864 Q34585272-3AFFF089-B896-4FF8-B63C-D45C7C349E57 Q34644756-D0706DCB-59DC-47D9-927F-1C2409005F6C Q34654243-AAF810A3-3A01-4263-ADC1-7C7D4FC7F892 Q34661961-EE158628-B776-4706-B1CB-399FA7FB45ED Q34667765-7CD8E071-A641-405D-B408-6FBD0E448F9C Q35009335-17D46EC7-9EC2-4E74-888C-A54CFC99FAC7 Q35092898-1DFDA50D-5D47-4C5A-97E8-117F8E4923C3 Q35112489-C6387F06-DDC6-4D08-85D2-75F214444F2C Q35153832-AB2E7B01-3301-4398-83FF-0D621630BCD0 Q35195954-A2A0208C-1468-4A62-A3F6-FA62824AA7C9 Q35198594-B9ECEA07-A6C1-4068-98F0-AFA3FB95506B Q35309808-BD292C4B-C1C8-466B-A28C-664CF79108D1 Q35421571-F3B921A0-AD63-4BAF-8DD5-93C44FFB7C8B Q35498937-A1A7BA96-5644-4CD1-BDAC-27D3A79044E6 Q35618761-FEAC3E33-2025-4A8A-B6D9-DFDC439190D3 Q35693060-FBDFAC29-18BD-4EB0-A26D-17AD97352EED Q35907790-658043A3-03A4-4058-97CE-9F567C47F30B Q36086954-A2CE668A-3F26-4E0F-8FCE-9590E95EBE03 Q36245820-15BA7B7A-1315-4C0F-BB58-D8E7FA1F46A5 Q36335887-DF609CA0-55DC-4E24-ADF5-41F7A07F5710 Q36832260-7EC46B31-C63F-4C29-9C10-92A6C45A4FAE Q36842357-DC88F3C7-9FBC-4FE1-AC1A-8F88FDC457BD Q36903076-F467BC12-EFB2-4907-A81B-8CCDB9511ABF Q36947409-FE172629-8B83-4683-AB77-C93D63416B11 Q37023594-28458A0F-2BC6-4915-8CBE-9CC3A242DEED Q37053219-59E36A4E-3AF3-42D3-974B-FA36489B0CB9 Q37670981-F15E5202-9C2A-47CE-B4D4-5624277D40E9 Q37726608-F7AC6F8D-AA82-4CC4-BD05-EC432D119F46 Q37886653-69461A3A-FAD7-4CBB-AFDB-54896AAF20BE Q37906737-25D91870-E13D-4914-96D9-F2984E4F85A4 Q37956169-74185DF5-CA01-448A-962F-E11F09E6A7B3 Q38023207-FA047310-2CD5-479A-A1FD-88E7AA471536 Q38116464-469BA501-73AA-47FB-8156-0C7F929B6661

P2860

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.

http://www.wikidata.org/entity/Q37480302

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Myositis-specific autoantibodi ...... ficance in disease expression.

@en

Myositis-specific autoantibodi ...... ficance in disease expression.

@nl

type

label

Myositis-specific autoantibodi ...... ficance in disease expression.

@en

Myositis-specific autoantibodi ...... ficance in disease expression.

@nl

prefLabel

Myositis-specific autoantibodi ...... ficance in disease expression.

@en

Myositis-specific autoantibodi ...... ficance in disease expression.

@nl

P1433

Q37480302-CEB36310-8368-4091-9DB6-818708F5BB22

P1476

Q37480302-94A0D7C6-DDB7-419B-8FD2-D15EE9032ED3

P2093

Q37480302-7EE3A946-6D9F-499F-91EB-F00E4915498D

Q37480302-90256579-BD77-47F3-873A-1100C3F9FAFD

Q37480302-E1AAEF27-A616-469B-ABEC-FA99784971B8

P2860

Q37480302-00EF4003-EBCB-48F7-B283-5517D1B0AE7C

Q37480302-17487BE1-FB39-4F3B-9C0A-D49E71946B0F

Q37480302-1F04C661-1F91-4B30-9118-C9A8610D8497

Q37480302-2C6CEF9D-7A1D-4346-83BA-366E0B30A6DB

Q37480302-2EE1D97E-4F35-4AB9-8AEB-AAFBB41F8BC9

Q37480302-32218DDA-F7DB-41E1-BA3D-2FCB4EF98742

Q37480302-344B1438-1320-47F3-BC28-8C5984C79384

Q37480302-36618D62-36ED-4FC1-8BFD-788A143EC9F5

Q37480302-3B27B950-A38C-42B6-9DA4-C84C1D7D5AEC

Q37480302-3B2B18F5-6D3A-43D7-A94A-8421F3F51B82

P304

Q37480302-602816BC-3C59-4365-9176-FB45F79BB334

P31

Q37480302-23264EDD-B6D4-4E44-9344-A5AF6424F907

P356

Q37480302-EEF1A1F7-0E5E-4D89-8283-FEC028FAFC6D

P433

Q37480302-A33FDA01-6307-4616-BCD6-67E909CF0915

P478

Q37480302-FCE260AF-4232-4A5E-9AF7-58B61D37426C

P577

Q37480302-9E0C1D45-2310-4F30-A62A-79C8939B41E6

P5875

Q37480302-3C7FA96A-52AA-4985-BAE8-7D0786BD4376

P698

Q37480302-BC69968E-228B-4B1E-A586-20534B88AEE2

P921

Q37480302-C5AD758B-22B2-48AF-A5C9-749304EFB9B0

P356

P1433

P1476

Myositis-specific autoantibodi ...... ficance in disease expression.

@en

P2093

Harsha Gunawardena

http://www.w3.org/2001/XMLSchema#string

Neil J McHugh

http://www.w3.org/2001/XMLSchema#string

Zoe E Betteridge

http://www.w3.org/2001/XMLSchema#string

P2860

NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression

The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains

Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis

Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.

Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis.

Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres.

Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.

Polymyositis and dermatomyositis (second of two parts).

Polymyositis and dermatomyositis (first of two parts).

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.

P304

607-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEP078

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24424735

http://www.w3.org/2001/XMLSchema#string

P698

19439503

http://www.w3.org/2001/XMLSchema#string

P921